Accordingly, in this post-hoc sub-study of the EMPA-HEART (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes) CardioLink-6 randomized control trial, we investigated the impact of SGLT2 inhibition with empagliflozin on parameters of LA size and function, and their relationship with natriuretic peptide and measures of LV diastolic function. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.